Analysts share of engagement, past 30 days. Past 24 hours from 1 mention.
Community
→The usual crowd
100% newcomers0% regulars
Newcomers share of engagement, past 30 days. Past 24 hours from 1 mention.
Sep 21
Social Summary
enVVeno Medical Corporation (formerly Hancock Jaffe) is transitioning from a development-stage to a commercialization-stage company, focusing solely on venous disease.
The company has mitigated capital and clinical risks, and its CEO believes that the investment community will soon catch up with the medical community's enthusiasm for its VenoValve product.
enVVeno Medical Corporation's stock has shown resilience in recent trading, with a notable up trend and a low float.
0.00011% of stock attention today30-day average 0.00011%
What people say
enVVeno Medical Corporation (formerly Hancock Jaffe) is transitioning from a development-stage to a commercialization-stage company, focusing solely on venous disease.
The company has mitigated capital and clinical risks, and its CEO believes that the investment community will soon catch up with the medical community's enthusiasm for its VenoValve product.
enVVeno Medical Corporation's stock has shown resilience in recent trading, with a notable up trend and a low float.